FASTIN Drug Patent Profile
✉ Email this page to a colleague
When do Fastin patents expire, and when can generic versions of Fastin launch?
Fastin is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in FASTIN is phentermine hydrochloride. There are seventeen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fastin
A generic version of FASTIN was approved as phentermine hydrochloride by ELITE LABS INC on May 30th, 1997.
Summary for FASTIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 44 |
Clinical Trials: | 2 |
Patent Applications: | 909 |
Formulation / Manufacturing: | see details |
DailyMed Link: | FASTIN at DailyMed |
Recent Clinical Trials for FASTIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Martin Blomberg Jensen | Phase 2 |
AstraZeneca | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for FASTIN
US Patents and Regulatory Information for FASTIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | FASTIN | phentermine hydrochloride | CAPSULE;ORAL | 017352-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |